ASH 2018 | RB/RC induction for mantle cell lymphoma: promising pooled analysis data
Reid Merryman
• 24 Jan 2019
Reid Merryman, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the pooled analysis of two Phase II clinical trials and off-trial experience of the induction chemotherapy regimen rituximab/bendamustine and rituximab/cytarabine for transplant-eligible mantle cell lymphoma (MCL), which he presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Merryman highlights the promising response rates and safety profile of the therapy.
